|Bid||67.28 x 0|
|Ask||67.30 x 0|
|Day's Range||67.20 - 67.30|
|52 Week Range||60.35 - 79.75|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
FRANKFURT (Reuters) - German healthcare group Fresenius (FREG.DE) will continue to look for acquisitions even if that leads to a temporary rise in debt, Boersen-Zeitung quoted the company's finance chief ...
German healthcare group Fresenius will continue to look for acquisitions even if that leads to a temporary rise in debt, Boersen-Zeitung quoted the company's finance chief as saying. Last year Fresenius ...
U.S. regulators warned Fresenius SE last month that workers in one of its cancer-drug plants ignored tests that found the products made there weren’t meeting sterility standards.
U.S. regulators warned Fresenius SE after the company’s Indian plant that makes cancer-drug ingredients for the U.S. market aborted hundreds of drug-quality tests because they seemed like they were going ...
Fresenius now expects its planned takeover of Akorn, a U.S. maker of liquid generic drugs, to be completed in early 2018 rather than this year, a spokesman for Fresenius said on Tuesday. "While we've been focused on a 2017 close, it's now clear that closing in early 2018 is more likely, and we're quite comfortable with this timeline," the spokesman said.
German healthcare group Fresenius SE (FREG.DE) said the planned takeover of Akorn (AKRX.O), a U.S. maker of liquid generic drugs, might not be completed before next year as the U.S. antitrust review could take longer than expected. Akorn's business has deteriorated since Fresenius struck the acquisition agreement in April, valuing the maker of medical creams, ophthalmic drugs and oral liquids at $4.75 billion (3.6 billion pounds). Akorn's operating income has slumped on supply disruptions and competition for a range of drugs.
German healthcare group Fresenius SE said on Thursday that weakness at Akorn , the U.S. maker of liquid generic drugs it has agreed to buy, could continue into next year but the deal was still worth it over the longer term. The 2018 targets for Akorn, which Fresenius plans to take over at the end of this year, were "challenging", the diversified drugmaker said in presentation slides posted on its website after the release of its quarterly results.
German healthcare group Fresenius said third-quarter adjusted net income gained 11 percent on higher drug sales and helped by the addition of Spanish hospitals chain Quironsalud. Quarterly net income adjusted ...
The billionaire founder of Insys Therapeutics Inc was arrested on Thursday on U.S. charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic. John Kapoor, Insys' majority shareholder who stepped down as chief executive in January, was charged with engaging in conspiracies to commit racketeering, mail fraud and wire fraud in an indictment filed in federal court in Boston. Following a court hearing in Phoenix, Kapoor, 74, was released on a $1 million bond.
New York-based Senvest Management is shorting three drug stocks, Insys Therapeutics Inc , Akorn Inc and Fresenius SE, its chief executive Richard Mashaal said on Tuesday, Speaking at the Sohn Conference ...
The Bad Homburg, Germany-based company said it had profit of 48 cents per share. The dialysis services provider posted revenue of $4.92 billion in the period. Fresenius shares have increased 12 percent ...
Nestle SA Chief Executive Officer Mark Schneider previously transformed a sleepy German hospital operator into a stock-market darling via more than 30 acquisitions. Now he wants to return to dealmaking ...
Activist investor Daniel Loeb's Third Point LLC on Sunday unveiled a more than 1 percent stake in Switzerland's Nestle SA and urged the world's largest packaged foods maker to improve its margins, buy back stock and shed non-core businesses. Third Point disclosed its Nestle position in a letter to investors, in which it argued the food company should sell its 23 percent stake in French cosmetics firm L'Oreal SA. "We feel strongly that in order to succeed, Dr. Schneider will need to articulate a decisive and bold action plan that addresses the staid culture and tendency towards incrementalism that has typified the company’s prior leadership and resulted in its long-term underperformance," Third Point wrote in the letter.
European shares slipped slightly from the 20-month highs they hit in the previous session, as investors locked in some profits following some underwhelming company results. Shares in several Apple suppliers fell after the smartphone giant reported a surprise dip in sales of its flagship iPhone. Dialog Semiconductor shares slid 2.9 percent at the open.
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion and the biosimilars unit of German peer Merck KGaA.
German healthcare group Fresenius SE & Co KGaA (FREG.DE) has stepped up its dealmaking, agreeing to buy U.S. generic drugmaker Akorn Inc (AKRX.O) for $4.75 billion (4.37 billion euros) and the biosimilars arm of Germany's Merck KGaA. Takeovers were part of Fresenius's growth strategy under previous boss Ulf Mark Schneider, now leading Nestle (NESN.S). The latest deals are in keeping with Fresenius's focus on drugs that have lost patent protection, but also mark a foray into new dosage forms, therapeutic areas and biotech drugs for its Kabi unit, a maker of generic infusion drugs as well as tube feeding and blood transfusion equipment.
In just 10 months at the head of Germany’s Fresenius SE, Chief Executive Officer Stephan Sturm has now inked the health-care provider’s two biggest-ever deals.